Responses to GLP ‐ 1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data
Authors' conclusion
In a large, diverse EHR cohort, GLP-1RA therapy was associated with significant weight, glycemic, and renal benefits that were attenuated in Black adults.
Study context
- Population
- Adults ≥18 years with BMI ≥30 kg/m² prescribed ≥1 injectable GLP-1RA, 2015–2025, University of Mississippi Medical Center
- Participants
- 7,214 adults
- Exposure
- White vs Black adults with obesity on GLP-1RA
- Whiten = 2,182
- Blackn = 5,032reference
- Outcome
- Body weight loss
- Follow-up
- 2.5 years
Methodological detailssingle-institution EHR data, generalized additive mixed models
- Single-institution EHR data
- Generalized additive mixed models
Main finding
As reported in the abstract
Body weight change
White
−7.1%
95% CI −8.0%–-6.2%
Black
−4.9%
95% CI −5.4%–-4.3%
Observational data: associations, not effects.
Further findings
eGFR, systolic blood pressure and HbA1c · 2.5 years
- Significantly larger reductions in eGFR, systolic blood pressure and HbA1c in White vs Black individuals
GLP-1RA agent
- Semaglutide and tirzepatide were associated with the greatest improvements
Renal function
- Renal function decline was attenuated in both groups after therapy
Original publication
Responses to GLP ‐ 1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data. Obesity (Silver Spring). Published 1 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →